ID

45760

Descrição

Principal Investigator: Manish Kohli, MD, Mayo Clinic, Rochester, MN, USA MeSH: Prostatic Neoplasms, Castration-Resistant,Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001141 The Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study uses genetic clues in castration-resistant prostate cancer that may identify an individualized treatment approach for men with the disease. Understanding the molecular biology behind castration-resistant prostate cancer has led to more treatment options, but there are still no definite conclusions about which specific drug best treats patients - maximum suppression of cancer growth while minimizing side effects. The PROMOTE study explores the genetic characteristics of each tumor to predict these treatment paradigms for the future, resulting in more effective and less toxic options for patients. Our long-term goal is to improve treatments for men with advanced prostate cancer by using genomic sequencing to increase life span and quality of life. We also will uncover novel vulnerable targets in the cancer genome that may provide new drug therapies. **PARTICIPATION** Eligible participants are men: - With castration-resistant prostate cancer or prostate cancer not responding to hormone treatments - About to begin abiraterone acetate therapy - Agreeable to undergoing two tumor biopsies During the study, participants travel to Mayo Clinic for an initial biopsy (before beginning abiraterone acetate) and a second biopsy approximately three months later. The cell tissue collected is analyzed to identify gene alterations in the tumor that could eventually be targeted with treatments. Tissue is preserved for future research. Participants can continue to be treated by their local cancer care team during this period and beyond. In addition, the Mayo team carefully monitors participants' cancer via follow-up studies and the genetic signature of tumors that were biopsied so that patients may benefit from future treatments.

Link

dbGaP-study=phs001141

Palavras-chave

Versões (1)
  1. 16/06/2023 16/06/2023 - Chiara Middel
Titular dos direitos

Manish Kohli, MD, Mayo Clinic, Rochester, MN, USA

Transferido a

16 de junho de 2023

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

  • Os mais recentes
  • Os mais antigos
  • Preferidos
  • Os mais recentes
    • Os mais recentes
    • Os mais antigos
    • Preferidos

Sem comentários

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

dbGaP phs001141 PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)

Inglês

Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.

5 Formulários  
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    3. Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    4. Subject ID, age, race, composite endpoint for progression after 12 weeks of abiraterone acetate chemotherapy, and sex of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    5. Sample ID, body site where sample was obtained, analyte type, primary or metastatic tumor, primary tumor location, tumor stage, tumor treatment, treatment post visit, histological type, sequence center, and body site category where sample was collected [bone or tissue] of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
pht005599
Descrição

pht005599

Alias
UMLS CUI [1,1]
C3846158
Subject ID
Descrição

SUBJECT_ID

Tipo de dados

string

Alias
UMLS CUI [1,1]
C2348585
Consent group as determined by DAC
Descrição

CONSENT

Tipo de dados

text

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C0441833
Source repository where subjects originate [Mayo Clinic Cancer Center]
Descrição

SUBJECT_SOURCE

Tipo de dados

string

Alias
UMLS CUI [1,1]
C3847505
UMLS CUI [1,2]
C0449416
UMLS CUI [1,3]
C0681850
Subject ID used in the Source Repository
Descrição

SOURCE_SUBJECT_ID

Tipo de dados

string

Alias
UMLS CUI [1,1]
C2348585
UMLS CUI [1,2]
C3847505
UMLS CUI [1,3]
C0449416
Case control status of the subject
Descrição

AFFECTION_STATUS

Tipo de dados

text

Alias
UMLS CUI [1,1]
C3274646
Voltar ao início da página

Similar models

Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.

5 Formulários
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    3. Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from Subject ID, consent group, subject source, source subject ID, and affection status of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    4. Subject ID, age, race, composite endpoint for progression after 12 weeks of abiraterone acetate chemotherapy, and sex of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
    5. Sample ID, body site where sample was obtained, analyte type, primary or metastatic tumor, primary tumor location, tumor stage, tumor treatment, treatment post visit, histological type, sequence center, and body site category where sample was collected [bone or tissue] of participants with castration resistant prostate cancer and involved in the "PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate" project.
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
pht005599
C3846158 (UMLS CUI [1,1])
SUBJECT_ID
Item
Subject ID
string
C2348585 (UMLS CUI [1,1])
Item
Consent group as determined by DAC
text
C0021430 (UMLS CUI [1,1])
C0441833 (UMLS CUI [1,2])
CONSENT
Code List
Consent group as determined by DAC
CL Item
General Research Use (GRU) (1)
C0021430 (UMLS CUI [1,1])
C0242481 (UMLS CUI [1,2])
SUBJECT_SOURCE
Item
Source repository where subjects originate [Mayo Clinic Cancer Center]
string
C3847505 (UMLS CUI [1,1])
C0449416 (UMLS CUI [1,2])
C0681850 (UMLS CUI [1,3])
SOURCE_SUBJECT_ID
Item
Subject ID used in the Source Repository
string
C2348585 (UMLS CUI [1,1])
C3847505 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,3])
Item
Case control status of the subject
text
C3274646 (UMLS CUI [1,1])
AFFECTION_STATUS
Code List
Case control status of the subject
CL Item
Control (1)
C3274648 (UMLS CUI [1,1])
CL Item
Case (2)
C3274647 (UMLS CUI [1,1])
CL Item
Other (3)
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial